Comparison of the modified Masood's scoring index versus international academy of cytology Yokohama system in the categorization of breast fine needle aspirates

IF 1.2 4区医学 Q4 CELL BIOLOGY

Cytopathology Pub Date : 2024-08-07 DOI:10.1111/cyt.13432

Adil Aziz Khan, Sana Ahuja, Shakthivel V, Sufian Zaheer, Sunil Ranga

{"title":"Comparison of the modified Masood's scoring index versus international academy of cytology Yokohama system in the categorization of breast fine needle aspirates","authors":"Adil Aziz Khan, Sana Ahuja, Shakthivel V, Sufian Zaheer, Sunil Ranga","doi":"10.1111/cyt.13432","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Context</h3>\n \n <p>The Modified Masood Scoring Index (MMSI) categorizes breast fine needle aspirates into four categories non-proliferative breast diseases (PBD), PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma. The International Academy of Cytology Yokohama System classifies the aspirates into five categories – inadequate, benign, atypical, suspicious, and malignant. Very few studies have been conducted so far to compare the diagnostic accuracy of this system.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>The objectives of the study were to classify breast fine needle aspirates according to the MMSI and IAC Yokohama and assess their risk of malignancy (ROM) and performance parameters.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>All breast FNAs received from June 2020 to May 2023 were classified according to the MMSI and IAC Yokohama. Using histopathological diagnosis as the gold standard, ROM and performance parameters were calculated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Out of the 559 breast fine needle aspirates, the histopathological correlation was available for 337 cases. The ROM for non-PBD, PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma categories were 0%, 1.2%, 9.1% and 93%, respectively. The ROM for each of the categories of Yokohama system was 16.6%, 1.1%, 4.3%, 86.2% and 97.6%, respectively. The values for the sensitivity, specificity, PPV, NPV and diagnostic accuracy were slightly higher for IAC Yokohama (97.3%, 97.2%, 94.7%, 98.6% and 97.2%, respectively) than the MMSI (96.4%, 96.2%, 93%, 98.1% and 96.3%, respectively). Furthermore, another shortfall of MMSI is the inability to compare the Inadequate category of the Yokohama system.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Overall Yokohama system proved to be a better system for categorizing breast lesions on FNAB as the scoring system provides more objective categorization and minimizes false positive and false negative cases.</p>\n </section>\n </div>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 6","pages":"706-714"},"PeriodicalIF":1.2000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cyt.13432","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context

The Modified Masood Scoring Index (MMSI) categorizes breast fine needle aspirates into four categories non-proliferative breast diseases (PBD), PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma. The International Academy of Cytology Yokohama System classifies the aspirates into five categories – inadequate, benign, atypical, suspicious, and malignant. Very few studies have been conducted so far to compare the diagnostic accuracy of this system.

Aims

The objectives of the study were to classify breast fine needle aspirates according to the MMSI and IAC Yokohama and assess their risk of malignancy (ROM) and performance parameters.

Materials and Methods

All breast FNAs received from June 2020 to May 2023 were classified according to the MMSI and IAC Yokohama. Using histopathological diagnosis as the gold standard, ROM and performance parameters were calculated.

Results

Out of the 559 breast fine needle aspirates, the histopathological correlation was available for 337 cases. The ROM for non-PBD, PBD without atypia, PBD with atypia and carcinoma in situ/carcinoma categories were 0%, 1.2%, 9.1% and 93%, respectively. The ROM for each of the categories of Yokohama system was 16.6%, 1.1%, 4.3%, 86.2% and 97.6%, respectively. The values for the sensitivity, specificity, PPV, NPV and diagnostic accuracy were slightly higher for IAC Yokohama (97.3%, 97.2%, 94.7%, 98.6% and 97.2%, respectively) than the MMSI (96.4%, 96.2%, 93%, 98.1% and 96.3%, respectively). Furthermore, another shortfall of MMSI is the inability to compare the Inadequate category of the Yokohama system.

Conclusion

Overall Yokohama system proved to be a better system for categorizing breast lesions on FNAB as the scoring system provides more objective categorization and minimizes false positive and false negative cases.

Abstract Image

查看原文本刊更多论文

改良马苏德评分指数与国际细胞学学会横滨系统在乳腺细针穿刺分类中的比较。

背景：改良马苏德评分指数（MMSI）将乳腺细针穿刺分为四类：非增生性乳腺疾病（PBD）、无不典型性乳腺疾病（PBD）、有不典型性乳腺疾病（PBD）和原位癌/癌。国际细胞学学会横滨系统将抽吸物分为五类--不充分、良性、非典型、可疑和恶性。目的：本研究的目的是根据 MMSI 和 IAC 横滨系统对乳腺细针穿刺进行分类，并评估其恶性风险（ROM）和性能参数：根据MMSI和IAC Yokohama对2020年6月至2023年5月期间接收的所有乳腺细针穿刺术进行分类。以组织病理学诊断为金标准，计算ROM和性能参数：结果：在559例乳腺细针穿刺中，337例有组织病理学相关性。非 PBD、无不典型性 PBD、有不典型性 PBD 和原位癌/癌类别的 ROM 分别为 0%、1.2%、9.1% 和 93%。横滨系统各分类的 ROM 分别为 16.6%、1.1%、4.3%、86.2% 和 97.6%。横滨 IAC 系统的灵敏度、特异性、PPV、NPV 和诊断准确度值（分别为 97.3%、97.2%、94.7%、98.6% 和 97.2%）略高于彩超系统（分别为 96.4%、96.2%、93%、98.1% 和 96.3%）。此外，MMSI 的另一个不足之处是无法比较横滨系统的不足类别：总体而言，横滨系统被证明是对 FNAB 乳腺病变进行分类的更好系统，因为该评分系统能提供更客观的分类，并能最大限度地减少假阳性和假阴性病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytopathology 生物-病理学

CiteScore

2.30

自引率

15.40%

发文量

107

审稿时长

6-12 weeks

期刊介绍： The aim of Cytopathology is to publish articles relating to those aspects of cytology which will increase our knowledge and understanding of the aetiology, diagnosis and management of human disease. It contains original articles and critical reviews on all aspects of clinical cytology in its broadest sense, including: gynaecological and non-gynaecological cytology; fine needle aspiration and screening strategy. Cytopathology welcomes papers and articles on: ultrastructural, histochemical and immunocytochemical studies of the cell; quantitative cytology and DNA hybridization as applied to cytological material.